+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Antibacterial Market (2021-2026) by Route of Administration, Drug Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • ID: 5392907
  • Report
  • April 2021
  • Region: Global
  • 168 Pages
  • Infogence Global Research

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • GlaxoSmithKline PLC
  • NacuGen Therapeutics Inc
  • R-Pharm Group
  • TenNor Therapeutics
The Global Antibacterial Market is estimated to be USD 26.3 Bn in 2021 and is expected to reach USD 40.65 Bn by 2026, growing at a CAGR of 9.1%.



Market Dynamics

The global antibacterial market is being driven by factors such as increased cases of bacterial infections, changing climatical condition that causes bacterial infection, growing number aged population, and rising demand for efficient and affordable antibacterial Drugs. Furthermore, the key factor predicted to boost the growth of the global antibacterial market is the rising incidence of bacterial illnesses and sickness throughout the world, rising healthcare spending, and businesses concentrating on the clinical development of drugs to treat severe bacterial infections. In addition, an increase in the number of product approvals and subsequent product launches and the government initiative and support for the health care sector is expected to create future opportunities for the growth of the global antibacterial market.

However, increasing cases of ecological toxicity, antibacterial medication side effects, and the presence of multidrug-resistant (MDR) bacteria which are important current threats to public health, are restraining and creating challenges for the growth of the Global Antibacterial Market expansion.

Market Segmentation

The Global Antibacterial Market is segmented further based on Route of Administration, Drug Class, Distribution Channel, and Geography.

By Route of Administration, the market is classified into enteral, parenteral. Amongst the two, the enteral segment is estimated to hold the highest market share during the forecast period.

By Drug Class, the market is classified as B lactams, quinolones, macrolides, tetracycline, aminoglycoside, sulfonamide, phenicols, others. Amongst all the, B lactams segment is estimated to hold the highest market share during the forecast period.

By Distribution Channel, the market is classified as hospital pharmacies, retail pharmacies, online pharmacies. Amongst all, the hospital pharmacies segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Micurx Pharmaceuticals Inc. has won marketing approval from China's NMPA for its lead antibacterial, contezolid, for treating adults with complicated skin and soft tissue infection. - 2nd June 2021.
2. Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent "Lasvic Tablets 75mg" - 20th September 2019.

Company Profiles

Some of the companies covered in this report AbbVie Inc, Allecra Therapeutics GmbH, Basilea Pharmaceutica Ltd, Bayer AG, Boston Pharmaceuticals Inc. etc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?
  • The report offers a comprehensive evaluation of the Global Antibacterial Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains a competitive analysis using the Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:
  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Antibacterial Market

What is the estimated value of the Global Antibacterial Market?

The Global Antibacterial Market was estimated to be valued at $26300.0 Million in 2021.

What is the growth rate of the Global Antibacterial Market?

The growth rate of the Global Antibacterial Market is 9.1%, with an estimated value of $40650.0 Million by 2026.

What is the forecasted size of the Global Antibacterial Market?

The Global Antibacterial Market is estimated to be worth $40650.0 Million by 2026.

Who are the key companies in the Global Antibacterial Market?

Key companies in the Global Antibacterial Market include AbbVie Inc, Allecra Therapeutics GmbH, Basilea Pharmaceutica Ltd, Bayer AG, Boston Pharmaceuticals Inc, Bristol Myers Squibb Company, Debiopharm Group, Eli Lilly and Company and Iterum Therapeutics PLC.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • GlaxoSmithKline PLC
  • NacuGen Therapeutics Inc
  • R-Pharm Group
  • TenNor Therapeutics

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Rising Occurrence of Infectious Diseases
4.1.2 Growing Approval and Launch of New Antibacterial Drugs
4.2 Restraints
4.2.1 Harmful Effects of Some Antibacterial
4.3 Opportunities
4.3.1 Government Initiatives in Healthcare Sector
4.3.2 Increasing R&D Activity
4.4 Challenges
4.4.1 Multi-Drug Resistant Bacterial Strains Presence
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Antibacterial Market, By Route of Administration
6.1 Introduction
6.2 Enteral
6.3 Parenteral
7 Global Antibacterial Market, By Drug Class
7.1 Introduction
7.2 B lactams
7.3 Quinolones
7.4 Macrolides
7.5 Tetracycline
7.6 Aminoglycoside
7.7 Sulfonamide
7.8 Phenicols
7.9 Others
8 Global Antibacterial Market, By Distribution Channel
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
9 Global Antibacterial Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 South America
9.3.1 Brazil
9.3.2 Argentina
9.3.3 Chile
9.3.4 Colombia
9.4 Europe
9.4.1 UK
9.4.2 France
9.4.3 Germany
9.4.4 Italy
9.4.5 Spain
9.4.6 Netherlands
9.4.7 Sweden
9.4.8 Russia
9.4.9 Rest of Europe
9.5 Asia-Pacific
9.5.1 China
9.5.2 Japan
9.5.3 India
9.5.4 Indonesia
9.5.5 Malaysia
9.5.6 South Korea
9.5.7 Australia
9.5.8 Sri Lanka
9.5.9 Thailand
9.5.10 Rest of APAC
9.6 Middle-East and Africa
9.6.1 Qatar
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 United Arab Emirates
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Strategic Initiatives
10.3.1 M&A and Investments
10.3.2 Partnerships and Collaborations
10.3.3 Product Developments and Improvements
11 Company Profiles
11.1 AbbVie Inc
11.2 Allecra Therapeutics GmbH
11.3 Basilea Pharmaceutica Ltd
11.4 Bayer AG
11.5 Boston Pharmaceuticals Inc
11.6 Bristol Myers Squibb Company
11.7 Debiopharm Group
11.8 Eli Lilly and Company
11.9 GlaxoSmithKline PLC
11.10 Iterum Therapeutics PLC
11.11 Johnson & Johnson Service, Inc
11.12 Kyorin Pharmaceutical Co., Ltd
11.13 Melinta Therapeutics Merck & Co., Inc
11.14 Micurx Pharmaceutical Inc
11.15 NacuGen Therapeutics Inc
11.16 Novartis International AG
11.17 Pfizer, Inc
11.18 R-Pharm Group
11.19 Sanofi SA
11.20 Shionogi Inc
11.21 Sichuan Pharmaceutical Co., Ltd
11.22 TenNor Therapeutics
11.23 Theravance Biopharma, Inc
11.24 VenatoRx Pharmaceuticals, Inc
11.25 Wockhardt Ltd
12 Appendix
12.1 Questionnaire
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Allecra Therapeutics GmbH
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • Boston Pharmaceuticals Inc
  • Bristol Myers Squibb Company
  • Debiopharm Group
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Iterum Therapeutics PLC
  • Johnson & Johnson Service, Inc
  • Kyorin Pharmaceutical Co., Ltd
  • Melinta Therapeutics Merck & Co., Inc
  • Micurx Pharmaceutical Inc
  • NacuGen Therapeutics Inc
  • Novartis International AG
  • Pfizer, Inc
  • R-Pharm Group
  • Sanofi SA
  • Shionogi Inc
  • Sichuan Pharmaceutical Co., Ltd
  • TenNor Therapeutics
  • Theravance Biopharma, Inc
  • VenatoRx Pharmaceuticals, Inc
  • Wockhardt Ltd
Note: Product cover images may vary from those shown